Evidence map›Paper›PMID 21969001›Full record

ArticleInfection and immunity2011

Functional promoter haplotypes of interleukin-18 condition susceptibility to severe malarial anemia and childhood mortality.

Samuel B Anyona, Prakasha Kempaiah, Evans Raballah, Collins Ouma, Tom Were, Gregory C Davenport, Stephen N Konah, John M Vulule, James B Hittner, Charity W Gichuki and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Infection and immunity, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Polymorphism in the Promoter Region of theFrontiers in immunology · 2020
    Trial
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Article
  7. AcuteFrontiers in microbiology · 2020
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. CCL3L1 copy number and susceptibility to malaria.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2012
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Samuel B AnyonaUniversity of New Mexico/Kenya Medical Research Institute, Laboratories of Parasitic and Viral Diseases, Centre for Global Health Research, Kisumu, Kenya.
Prakasha Kempaiah
Evans Raballah
Collins Ouma
Tom Were
Gregory C Davenport
Stephen N Konah
John M Vulule
James B Hittner
Charity W Gichuki
John M Ong'echa
Douglas J Perkins
Kenya Medical Research Institute · KECenter for Global Health · USKenyatta University · KECollege of Charleston · USMaseno University · KEUniversity of New Mexico · US

Funding

TRAINING AND RESEARCH ON SEVERE MALARIAL ANEMIAD43TW005884 · FIC · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Collins Ouma, Douglas Jay Perkins · 2002 to 2026
$5.2M
Biology of Infectious Diseases &InflammationT32AI007538 · NIAID · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Michelle A Ozbun · 1998 to 2026
$5.2M
GENETIC BASIS OF SEVERE MALARIAL ANEMIAR01AI051305 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PERKINS, DOUGLAS JAY · 2002 to 2011
$4.7M
FIC NIH HHS 1 D43TW05884FIC NIH HHS D43 TW005884NIAID NIH HHS R01 AI051305NIAID NIH HHS T32 AI007538PHS HHS 1 R01A151305
6 · The paper itself

Abstract

Severe malarial anemia (SMA) is a leading cause of morbidity and mortality in children residing in regions where Plasmodium falciparum transmission is holoendemic. Although largely unexplored in children with SMA, interleukin-18 (IL-18) is important for regulating innate and acquired immunity in inflammatory and infectious diseases. As such, we selected two functional single-nucleotide polymorphisms (SNPs) in the IL-18 promoter (-137G→C [rs187238] and -607C→A [rs1946518]) whose haplotypes encompass significant genetic variation due to the presence of strong linkage disequilibrium among these variants. The relationship between the genotypes/haplotypes, SMA (hemoglobin [Hb], <5.0 g/dl], and longitudinal clinical outcomes were then investigated in Kenyan children (n = 719). Multivariate logistic regression analyses controlling for age, gender, sickle cell trait, glucose-6-phosphate dehydrogenase (G6PD) deficiency, HIV-1, and bacteremia revealed that carriage of the -607AA genotype was associated with protection against SMA (odds ratio [OR] = 0.440 [95% confidence interval {CI} = 0.21 to 0.90], P = 0.031) in children with acute infection. In contrast, carriers of the -137G/-607C (GC) haplotype had increased susceptibility to SMA (OR = 2.050 [95% CI = 1.04 to 4.05], P = 0.039). Measurement of IL-18 gene expression in peripheral blood leukocytes demonstrated that elevated IL-18 transcripts were associated with reduced hemoglobin concentrations (ρ = -0.293, P = 0.010) and that carriers of the "susceptible" GC haplotype had elevated IL-18 transcripts (P = 0.026). Longitudinal investigation of clinical outcomes over a 3-year follow-up period revealed that carriers of the rare CC haplotype (∼1% frequency) had 5.76 times higher mortality than noncarriers (P = 0.001). Results presented here demonstrate that IL-18 promoter haplotypes that condition elevated IL-18 gene products during acute infection are associated with increased risk of SMA. Furthermore, carriage of the rare CC haplotype significantly increases the risk of childhood mortality.

Indexed as

Infant MortalityAnemiaFemaleGene Expression RegulationGenetic TestingGenetic VariationHaplotypesHumansInfantInterleukin-18KenyaLinkage DisequilibriumMalaria, FalciparumMaleOdds RatioPromoter Regions, GeneticInterleukin-18

Identifiers

PMID21969001
PMCPMC3232671
OpenAlexW2165504995

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.